Sarah Dry

David Geffen School of Medicine at UCLA
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (9)

Year:

2026

Ewing Sarcoma (ES) is a rare but aggressive malignancy of bone tissue in adolescents and young adults, where early detection of progression and real‐time treatment monitoring remain unmet clinical needs. Tumor extracellular vesicles (EVs) carry surface markers and nucleic acid cargo that can serve as minimally invasive biomarkers, but single‐marker EV assays often lack specificity, and colocalized‐marker approaches may suffer from low sensitivity. Here, we report the ES EV Capture–Release–Capture (CaReCa) assay, a two‐step enrichment strategy that combines desthiobiotin (DTB)‐mediated capture/release of CD99 + EVs with click chemistry‐mediated recapture of CD99 + /B7‐H3 + EVs, introducing molecular specificity to suppress background signals. To overcome limited yield from EVs with colocalized markers, we incorporated RT‐digital PCR quantification of encapsulated ACTB mRNA, a stable housekeeping transcript, as a sensitive proxy for EV abundance. Using only 100 µL of plasma, the ES EV CaReCa assay distinguished ES patients ( n = 20) from healthy donors ( n = 20) with an AUROC of 0.98. Longitudinal analysis further demonstrated that dynamic changes in the assay readouts paralleled disease progression and treatment response, consistent with PET/CT findings. Together, these results establish CaReCa as a sensitive, specific, and scalable liquid biopsy platform with translational potential for noninvasive monitoring of ES patients.

Year:

2026

Aims Rhabdomyosarcoma (RMS) is rare, but it is the most common sarcoma in childhood. The World Health Organisation classifies RMS into four main categories, sharing the same terminology of RMS, but the subtypes have different morphology, clinical behaviour and underlying molecular characterisation. Although the main diagnostic categories have remained the same there have been changes in the histological criteria, together with integration of both immunohistochemical and molecular data in the reporting of RMS. Integrated histology reporting provides valuable information for the management of children with RMS, is important for patients enrolled into clinical trials, supports tissue‐based biological research and contributes to data required in cancer registries. Consistent, comprehensive and reproducible reporting of RMS is imperative. Methods and results In this article we provide the International Collaboration on Cancer Reporting (ICCR) process for the development of the first international Paediatric RMS data set for the reporting of biopsy and resection specimens. An international expert panel consisting of pathologists and paediatric oncologists produced a set of core and non‐core elements to be included in the histopathology reporting of paediatric RMS, inclusive of clinical, macroscopic, microscopic and ancillary testing required for a comprehensive report. The selection of data items was based on review of current evidence, taking into account items that are recognised as essential for patient treatment stratification and that are currently in use in the clinical trial setting. Commentary was provided for each data item to detail the rationale for selecting it as core or non‐core element, and to highlight their clinical relevance. Conclusions The first international data set for the reporting of paediatric RMS aims to promote standardised, high‐quality reporting and supports uniform data collection, which is critical for clinical data comparison on a global level, ultimately improving patient outcome.

Year:

2025

Osteosarcoma (OS), the most common bone cancer in children, is characterized by aggressive tumors and subclinical metastasis. Metastasis significantly impacts OS patient survival rate, highlighting the need for frequent assessment of disease progression and treatment response. The study introduces OS extracellular vesicles (EV) matrix metalloproteinase (MMP) Activity Assay, noninvasively analyzing six combinations of OS EV surface markers and OS‐associated MMPs to generate a unique OS EV MMP profile for each patient. An OS EV MMP Activity Score is established from logistic regression of three top‐performing combinations to specifically distinguish metastatic OS from localized OS, achieving an area under the receiver operating characteristic (AUROC) curve of 0.97. The Scores from longitudinal monitoring of six OS patients strongly correlate with disease progression and treatment response, as confirmed by radiographic imaging. The OS EV MMP Activity Assay enables noninvasive and timely monitoring of disease progression and treatment response during the critical disease window of progression to metastatic OS, enhancing clinical management for OS patients.

Year:

2025

Well-differentiated and dedifferentiated liposarcoma (WD/DD LPS) represent a pathological continuum, often coexisting within the same tumor. While the dedifferentiated component is clinically aggressive, marked by rapid growth and metastatic potential, the evolutionary relationship between WD and DD LPS remains unknown. To investigate this, we performed single-nucleus RNA sequencing on matched WD and DD tumor regions. Both compartments shared a predominant population of undifferentiated mesenchymal cells, but only WD regions contained cells expressing adipocytic differentiation markers and PPARG target genes. Given the central role of PPARG in coordinating lipid metabolism and mitochondrial biogenesis during adipogenesis, these findings suggest that loss of this program may underlie the poorly differentiated, proliferative phenotype of DD LPS. Functional studies confirmed that PPARG activation in DD LPS cells induces lipid accumulation, reduces proliferation, and impairs tumor growth in vivo . These support a model in which impaired adipogenic differentiation underlies DD LPS pathology and identify PPARG as a potential therapeutic target to promote differentiation and suppress tumor progression. Teaser PPARG reprograms DD liposarcoma toward adipogenesis, reducing proliferation and tumor growth

Year:

2025

Year:

2024

Year:

2021

Year:

2021

Year:

2021

Collaborators (15)

Blake Wilde

Assistant Professor

Roswell Park Comprehensive Cancer Center

UNITED STATES
View details

Carrie Wong

University of California, Los Angeles

UNITED STATES
View details

Yazhen Zhu

Assistant Professor

David Geffen School of Medicine at UCLA

UNITED STATES
View details

Hsian-Rong Tseng

Professor

David Geffen School of Medicine at UCLA

UNITED STATES
View details

Alice Soragni

University of California

UNITED STATES
View details

Kelly M. Bailey

Associate Professor, Director AYA Translational Oncology

Mayo Clinic

UNITED STATES
View details

Miguel Reyes-Mugica

Clinical Professor of Pathology. Division Director of Pediatric and Developmental Pathology

University of Miami Miller School of Medicine

UNITED STATES
View details

Qiao Liu

Assistant Professor

Yale University

UNITED STATES
View details

Jessica L. Davis

Indiana University School of Medicine

UNITED STATES
View details

William Hsu

Professor

University of California, Los Angeles

UNITED STATES
View details

Lopa Mishra

Merinoff Endowed Chair and Professor of Medicine and Co-Director, The Institute for Bioelectronic Medicine

Northwell Health Feinstein Institutes for Medical Research

UNITED STATES
View details

Joseph Crompton

Assistant Professor, Division of Surgical Oncology

UCLA Health

UNITED STATES
View details

Heather Christofk

Professor

David Geffen School of Medicine at UCLA

UNITED STATES
View details

Brian Kadera

Assistant Professor of Surgery

David Geffen School of Medicine at UCLA

UNITED STATES
View details

Sungyong You

Professor

Cedars-Sinai Medical Center

UNITED STATES
View details